rs112445441
|
|
|
0.100 |
GeneticVariation |
BEFREE |
This unique trial will yield prospective information on the efficacy of cetuximab and whether this is further enhanced with chemotherapy in two distinct populations of patients with metastatic colorectal cancer: the "quadruple wild type", which may 'superselect' for tumours sensitive to EGFR-inhibition, and the rare KRAS G13D mutated tumours, which are also postulated to be sensitive to the drug.
|
27246726 |
2016 |
rs112445441
|
|
|
0.100 |
GeneticVariation |
BEFREE |
We found K-ras(G13D) mutation to occur at far greater incidence in cells derived from xenografted tumors or exposed to conditions of combined hypoxia and hypoglycemia in vitro.
|
16166287 |
2005 |
rs112445441
|
|
|
0.100 |
GeneticVariation |
BEFREE |
KRAS exon 2 mutation variants were associated with heterogeneous outcome compared with unmutated tumors with KRAS G12C and G13D (trend) being associated with rather poor survival.
|
27358379 |
2016 |
rs112445441
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Compared to patients with c.38G > A (rs112445441, p.G13D), patients with c.*4066delA (rs560890523) and c.38G > A (rs112445441, p.G13D) presented more aggressive tumors with highly invasive features.
|
27256640 |
2017 |
rs112445441
|
|
|
0.100 |
GeneticVariation |
BEFREE |
We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) to evaluate whether the efficacy of anti-EGFR mAbs for mCRC differs between tumours harbouring a KRAS G13D mutation (KRAS G13D) and KRAS mutations other than G13D (other KRAS MT).
|
26812186 |
2016 |
rs112445441
|
|
|
0.100 |
GeneticVariation |
BEFREE |
However, G12V mutations appeared to be associated with higher rates of tumor regression than G13D mutations (p=0.012).
|
19913317 |
2010 |
rs112445441
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Ongoing controversies such as whether patients with KRAS G13D- (or BRAF V600-) mutated tumours can still respond to EGFR-targeted mAbs and the potential impact of inter- and intra-tumour heterogeneity on tumour sampling show that the usefulness of KRAS as a biomarker has not yet been exhausted, and that other downstream biomarkers should be considered.
|
23375249 |
2013 |
rs112445441
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In this analysis, use of cetuximab was associated with longer overall and progression-free survival among patients with chemotherapy-refractory colorectal cancer with p.G13D-mutated tumors than with other KRAS-mutated tumors.
|
20978259 |
2010 |
rs112445441
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Prior to treatment there were significant metabolic differences between SW48 WT and SW48-KRAS-G13D tumors, reflecting higher oxidative stress and glucose utilization in the KRAS-G13D tumors.
|
26709701 |
2015 |
rs112445441
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Participating laboratories contributed information on KRAS mutation frequencies, including the G13D mutation type, as well as turnaround times for tumor block retrieval and testing.
|
24811330 |
2014 |
rs112445441
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Patients who had mCRC with the KRAS p.G13D mutation appeared to benefit more from cetuximab than patients who had tumors with KRAS codon 12 mutations.
|
22972628 |
2013 |
rs112445441
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Whereas, the KRAS mutation p.Gly13Asp have been detected only in MSI-H. 43.75 % of the patients harboured combined mutations in KRAS and TP53 genes and the tumor of 71.42 % of them showed TP53 overexpression.
|
24078161 |
2013 |
rs112445441
|
|
|
0.100 |
GeneticVariation |
BEFREE |
However, a recent report suggested that the use of cetuximab was associated with survival benefit among patients with p.G13D-mutated tumors.
|
22043994 |
2012 |
rs112445441
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Although the G13D KRAS mutation normally predicts an intermediate outcome, the aggressive tumor behavior suggests other modifying factors in rare types of colonic carcinomas.
|
22180717 |
2011 |
rs112445441
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Patients with KRAS wild-type tumors have a longer progression-free survival (7.30 months [95% CI, 4.48-10.12 months]; HR 0.46 [95% CI, 0.23-0.91]; P = .025) and overall survival (19.0 months [95% CI, 10.2-27.8 months]; HR 0.32 [95% CI, 0.15-0.69]; P = .004) than patients with p.G13D-mutated tumors.
|
22537608 |
2012 |
rs112445441
|
|
|
0.100 |
GeneticVariation |
BEFREE |
KRas G12V primary tumors showed Akt activation, and β5 integrin, vascular endothelial growth factor A (VEGFA), and Serpine-1 overexpression, whereas KRas G13D tumors showed integrin β1 and angiopoietin 2 (Angpt2) overexpression.
|
25359494 |
2015 |
rs112445441
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Mutations in primary tumors were identified in three regions; KARS (G13D) and APC (R876*) in P1-2, TP53 (A161S) in P1-3, and KRAS (G12D), PIK3CA (Q546R), and ERBB4 (T272A) in P1-4.
|
25623536 |
2015 |
rs112445441
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Furthermore, we observe an in vivo reduction in tumor size of gallbladder xenografts in response to Afatinib is paralleled by a reduction in the amounts of phospho-ERK, in tumors harboring KRAS (G13D) mutation but not in KRAS (G12V) mutation, supporting an essential role of the ErbB pathway.
|
30304546 |
2019 |
rs112445441
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The addition of cetuximab to first-line chemotherapy seems to benefit patients with KRAS G13D-mutant tumors.
|
22734028 |
2012 |
rs121913529
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Orthotopic implantation of PDCs carrying the activated Kras(G12D</span>)-allele and shRNA against p16(Ink4a) or Trp53 resulted in tumor growth, metastasis, and reduced survival of NSG mice.
|
25724428 |
2015 |
rs121913529
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In conclusion, whilst oncogenic KRAS mutation might activate Yap in other cell types, we could find no evidence for this in myoblasts because the expression of KRAS G12V expression did not change Yap/Taz activity in myoblasts and there was a limited overlap in gene expression between KRAS G12V and YAP1 S127A-driven tumours.
|
30353028 |
2018 |
rs121913529
|
|
|
0.100 |
GeneticVariation |
BEFREE |
When the assay was applied to tumor samples with known KRAS or NRAS mutations (G12A, G12D, G12V, and G13D), RAS-mutant and wild-type peptides were successfully detected in 11 of 13 biopsy samples.
|
29684684 |
2018 |
rs121913529
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Coactivation of BRAF(V600E) and KRAS(G12D) markedly reduced lung tumor numbers and overall tumo</span>r burden compared with activation of BRAF(V600E) alone.
|
26028035 |
2016 |
rs121913529
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Moreover, we show that KRAS(G12D)- and BRAF(V600E)-induced tumor formation in an orthotopic model requires IGF1R.
|
22871572 |
2012 |
rs121913529
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Mice with a combined Tsc1-Kras(G12D) mutation had dramatically reduced tumor latency (median survival: 11.6-15.6 weeks) in comparison with Kras(G12D) alone mutant mice (median survival: 27.5 weeks).
|
19966866 |
2010 |